6 inhibitor palbociclib in combination with metformin in two-dimensional (2D) and three-dimensional (3D) HGSOC cultures. **Methodology** Four ovarian cancer cell lines were treated with palbociclib, or metformin, or combination of both agents. Cell viability was assessed using MTT assays and cell cycle arrest was detected using flow cytometry. Subsequently, the results were validated using 3D-tumor spheroid model.

Result(s)* A significant decrease in cell viability was detected in all four ovarian cancer cell lines under treatment with palbociclib (-99.5% in A2780; -97% in BIN67; -84% in OVCAR3; -61.4% in SKOV6), under treatment with metformin (-85.18%; -75.34%; -86.40%, -62.96%, respectively) and under treatment with the combination of both (-99.6%; -94.9%; -85.8%; -76.9%, respectively). Subsequently, the results were confirmed in 3D tumor spheroid model, where both agents showed synergetic anticancer efficacy. Both agents promoted cell cycle arrest in all four 2D cell lines.

Conclusion* Combination of CDK inhibitor palbociclib and metformin showed high anti-cancer efficacy in 5 ovarian cancer cell lines and in the three-dimensional tumor spheroid model. This effect is probably due to cyclin D-driven cell cycle arrest. Thus, cyclin/CDK pathway represents a novel therapeutic target in ovarian cancer.

718

INVESTIGATING IMPACT OF ULTRA-RADICAL SURGERY IN ADVANCED OVARIAN CANCER USING POPULATION LEVEL DATA LINKED TO THE SOCQER 2 MULTICENTRE STUDY

¹SS Sundar*, ²C Cummins, ³J Balega, ⁴T Broadhead, ⁵T Duncan, ⁶R Edmondson, ⁷C Fotopoulou, ⁸D Kolomainen, ²S Kumar, ⁹R Manchanda, ¹⁰J Morrison, ¹¹J Tidy, ¹²N Wood. ¹Institute of Cancer and Genomic Sciences, University of Birmingham, UK; ²University of Birmingham, Institute of Applied Health Research, Birmingham, UK; ³Pan Birmingham gynaecological cancer centre, City Hospital, Birmingham; ⁴Leeds Hospital NHS trust; ⁵Norfolk and Norwich University Hospitals NHS trust; ⁶University of Manchester; ⁷Imperial University Hospitals NHS trust; ⁸Southend Hospitals NHS trust; ⁹Barts and the London Hospitals NHS trust; ¹⁰Taunton Hospitals NHS Trust; ¹¹Sheffield Hospitals NHS trust; ¹²Lancashire Hospitals NHS trust

10.1136/ijgc-2021-ESGO.452

Introduction/Background* The first population study investigating per protocol implementation of ultra-radical surgery (URS) as primary surgery reported that URS in advanced ovarian cancer (AOC) reduces the proportion treated surgically and does not improve survival.¹ We investigated this hypothesis using population level data for centers participating in the SOCQER 2 study

Abstract 718 Table 1 Proportion of treatment received in centres participating in the SOCQER2 study—population data analysis. Stage 3, 4 and stage unknown patients

	Proportion of treatment received in centres participating in the SOCQER2 study – population data analysis. Stage 3,4 and stage unknown patients.					
	Centres with >70% low SCS surgery (5/11 participating centres)		Centres with low SCS 35-50% and > 40% intermediate SCS surgery (3/11 participating centres).		Centres with >35% high SCS surgery (3/11 participating centres)	
Treatment within cancer network	N	%	n	%	n	%
No resection surgery/no chemotherapy	220	27.9	96	26.3	95	25.8
Chemotherapy only	217	27.5	55	15.1	83	22.6
Resection surgery only	42	5.3	25	6.8	49	13.3
Resection surgery and chemotherapy	309	39.2	189	51.8	141	38.3

Surgical treatment in the Socqer2 study	95% Confidence Interval			
	Median	Std. Error	Lower Bound	Upper Bound
Centres with >70% low SCS surgery	18.859	1.244	16.420	21.298
Centres with mainly low (35-50%) and > 40% intermediate SCS surgery	22.473	2.180	18.200	26.745
Centres with >35% high SCS surgery	24.017	1.810	20.469	27.565
Overall	20.929	1.009	18.950	22.907

Abstract 718 Figure 1 Kaplan Meir Survival curve. Log rank test $p=0.051$

Methodology The SOCQER2 study investigated quality of life after surgery of varying complexity for AOC in a prospective multicenter cohort study, recruiting for 12 months with 24 months follow-up. Results of QoL and variation in Surgical Complexity Scores (SCS) have been previously reported.² SOCQER2 centers diverged in approach to URS; used routinely in some participating centers and not in others. Here we analyzed data from nationally collected datasets (Cancer Outcome and Services Data, Systemic Anti-Cancer Treatment, Hospital Episode Statistics) to investigate survival and treatment outcomes in the total cohort of patients from the cancer centers that participated in the SOCQER 2 study, including patients with FIGO Stage 3,4, and stage unknown AOC patients. Residual disease post-surgery was not available for analysis.

Result(s)* 1521 patients across 11 participating centers clustered into 3 groups – centers performing >70% low SCS (5/11), mainly intermediate SCS >40% (3/11) and mainly high SCS surgery > 35% (3/11) with 788, 365 and 368 patients. The proportion of patients receiving standard of care, surgery and chemotherapy, was similar in both low and high SCS groups and highest in the intermediate group (39.2 vs 38.3 vs 51.8, $p<0.000$) (table 1). Median survival was 24.0 vs 22.4 vs 18.8 months in the high, intermediate and low SCS centers, log rank test $p=0.051$, (figure 1).

Conclusion* This multicenter ‘real-life’ population based study finds that URS does not reduce the proportion of AOC patients treated surgically. Centers with mainly intermediate SCS have higher proportion receiving surgery and chemotherapy; this may reflect a willingness to accept greater optimal rather than complete cytoreduction rates. Centers with greater radicality trend towards improved survival, but this did not reach statistical significance. A larger population level study to identify ideal intermediate: high SCS ratios is urgently needed.

721

YOLK SAC OVARIAN TUMOR, IS ALWAYS FERTILITY PRESERVATION POSSIBLE?, REPORT OF THREE CASES AND REVIEW OF LITERATURE

¹F Behnamfar*, ¹M Nazemi, ²B Mohamadi. ¹Isfahan University of Medical Sciences, Women's oncology, Isfahan, Iran; ²Isfahan University of Medical Sciences, Pathology, Isfahan, Iran

10.1136/ijgc-2021-ESGO.453

Introduction/Background* Yolk sac ovarian tumors are rare, 2]. Surgery is required for diagnosis, staging, and treatment. Yolk

sac tumor was universally life-threatening before the development of combination chemotherapy. With the introduction of novel chemotherapeutic regimens, especially adding cisplatin to combination therapies, prognosis of the patients reached excellent values, even for patients with advanced stages.

Methodology

Result(s)* Case 1: A 12 years old girl presented in march 2018 with complain of abdominal pain. The ultrasonography (US) showed a huge pelvic solid tumor. AFP level was high (1200 mg/ml). Right salpingoophorectomy and pelvic lymphadenectomy were done. Histopathology revealed Yolk sac tumor limited to the ovary. Rising of AFP happened four months after the surgery and normalization of the marker. Imaging showed no gross disease. She received 3 courses of (Bleomycin, Etoposide and Cisplatin) and has been in remission. Menses restarted after six months of the last course of chemotherapy.

Case 2: A 25 years old woman G2Ab1L1 presented in May 2016 with severe abdominal pain and distension. The abdominal ultrasonography showed a huge heterogeneous solid cystic lesion and free fluid. AFP level was 1000 mg/ml. Laparotomy was done. Ruptured fragmented right ovarian tumor, hemoperitoneum and tumor involving omentum and appendix were found. Right salpingoophorectomy, omentectomy, appendectomy and tumor debulking was done. Histopathology revealed Yolk sac tumor. She received four cycles of BEP. AFP level decreased to normal after the fourth cycle. She has been in remission, normally menstruating in the past five years.

Case 3: A 21 years old girl presented in September 2020 with complain of abdominal pain. The ultrasonography (US) showed a large solid pelvic tumor originating from right adnexa. AFP level was high (8700 mg/ml). Rt salpingoophorectomy, pelvic and paraaortic lymphadenectomy were done. Tumor was ruptured intraoperatively.

Histopathology report revealed Yolk sac tumor limited to ovary. She received 3 courses of BEP regimen. Her menses resumed five months after the last chemotherapy course and has been in remission.

Conclusion* These cases remind us, in adolescence and young age with solid high AFP levels and rapidly growing ovarian mass, diagnosis of the Yolk sac tumor has to be kept in mind. Long term remission and preservation of fertility seem to be possible when definite surgery and chemotherapy with BEP regimen is used.

723

NEW ALGORITHM TO ASSESS THE RISK OF MALIGNANCY IN PREMENOPAUSAL PATIENTS WITH PELVIC MASS

^{1,2}M Katsyuba*, ¹R Khasanov, ³T Madzhidov, ⁴G Usmanova, ⁵G Muratova, ⁴A Akhmetzianova, ²G Fakhrutdinova, ^{1,2}V Terenteva, ³A Rakhimbekova. ¹Kazan State Medical Academy – Branch Campus of the FSBEI FPE RMACPE MOH Russia, Oncology, Kazan, Russian Federation; ²Kazan Clinical Cancer Center, Gynecological Oncology, Kazan, Russian Federation; ³A.M. Butlerov Institute of Chemistry, Kazan Federal University, Kazan, Russian Federation; ⁴Kazan Clinical Cancer Center, Laboratory medicine, Kazan, Russian Federation; ⁵Kazan Federal University, International preparatory school, Kazan, Russian Federation

10.1136/ijgc-2021-ESGO.454

Introduction/Background* Human epididymis protein 4 (HE4) has been reported as a promising biomarker in the assessment of the risk of malignancy in patients, diagnosed with pelvic mass. However, reference limits of HE4 do not provide clinically relevant discrimination between malignant and benign